Physician

Jeffrey H. Margolis, M.D.

According to 2025 Medicare claims, Jeffrey Margolis, M.D. (NPI: 1871577544) practices hematology/oncology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Oakland, MI. This provider's primary affiliated billing organization is MICHIGAN HEALTHCARE PROFESSIONALS PC (NPI: 1295023547; TIN: 451674932) and primary practice location at 48073-9998. Margolis is affiliated with the Honest ACO of Michigan LLC (ACO ID: D0236), participating under the REACH model.

Margolis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 898 traditional Medicare patients, billed 385,662 HCPCS/CPT codes, and received $6,767,962 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 5,808 prescription claims across 757 beneficiaries totaling $13,155,919 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 16 claims. Open Payments data shows 5 records totaling $103,349. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $3,443,059 to $6,767,962. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $3,236,814 to $13,155,919. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,058 to $688.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	939	219,675	$3,443,059
2016	871	248,838	$2,982,561
2017	974	293,572	$5,216,042
2018	1,015	322,034	$5,495,214
2019	1,089	364,212	$7,088,869
2020	978	311,489	$6,338,953
2021	917	274,745	$5,977,764
2022	894	337,108	$6,062,067
2023	905	351,336	$6,497,509
2024	898	385,662	$6,767,962

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	671	4,554	$3,236,814
2016	616	4,699	$4,990,675
2017	626	4,664	$5,858,370
2018	686	5,119	$7,817,689
2019	733	5,296	$8,706,526
2020	690	5,150	$9,090,346
2021	694	4,816	$8,110,670
2022	703	5,036	$9,666,101
2023	722	5,437	$11,960,271
2024	757	5,808	$13,155,919

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	70	$36,434
2016	25	79	$26,409
2017	12	146	$28,339
2018	N/R	154	$14,241
2019	N/R	106	$8,199
2020	N/R	123	$35,183
2021	N/R	83	$5,042
2022	N/R	112	$4,472
2023	N/R	62	$7,535
2024	N/R	16	$628

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	435	1,144	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	611	1,508	$69
80047	Blood test, basic group of blood chemicals (calcium, ionized)	627	2,633	$13
96372	Injection of drug or substance under skin or into muscle	187	675	$11
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	592	2,865	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	144	4,036	$2,312,123
Ibrance	Palbociclib	117	3,276	$1,842,795
Revlimid	Lenalidomide	49	1,309	$959,917
Tagrisso	Osimertinib Mesylate	50	1,500	$841,535
Pomalyst	Pomalidomide	32	896	$745,849

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$628

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$315	HISTOSONICS,INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$103,034	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey H. Margolis, M.D.?

Tedicare shows public-source Medicare data for Jeffrey H. Margolis, M.D. (NPI 1871577544), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey H. Margolis, M.D. have ACO affiliation data?

Jeffrey H. Margolis, M.D. is shown with ACO affiliation data for Honest ACO of Michigan LLC (REACH, ACO ID D0236).

What billing organization is linked to Jeffrey H. Margolis, M.D.?

Jeffrey H. Margolis, M.D. is linked to MICHIGAN HEALTHCARE PROFESSIONALS PC (billing NPI 1295023547) in the available physician profile data.

Does Jeffrey H. Margolis, M.D. have Open Payments data?

Jeffrey H. Margolis, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.